|1.||Masliah, Eliezer: 8 articles (05/2009 - 08/2002)|
|2.||Hashimoto, Makoto: 7 articles (05/2009 - 08/2002)|
|3.||Wei, Jianshe: 3 articles (05/2009 - 10/2006)|
|4.||Fujita, Masayo: 3 articles (05/2009 - 10/2006)|
|5.||Nakai, Masaaki: 3 articles (05/2009 - 10/2006)|
|6.||Mor, Felix: 3 articles (03/2009 - 01/2003)|
|7.||Rockenstein, Edward: 3 articles (09/2007 - 08/2002)|
|8.||Wright, Josephine A: 2 articles (11/2013 - 01/2011)|
|9.||McHugh, Patrick C: 2 articles (11/2013 - 01/2011)|
|10.||Brown, David R: 2 articles (11/2013 - 01/2011)|
|1.||Parkinson Disease (Parkinson's Disease)
06/15/2007 - "Beta-synuclein gene variants and Parkinson's disease: a preliminary case-control study."
10/01/2002 - "Development of new treatments for Parkinson's disease in transgenic animal models: a role for beta-synuclein."
07/09/1999 - "No pathogenic mutations in the beta-synuclein gene in Parkinson's disease."
11/15/1998 - "We have observed that the beta-synuclein gene (HGMW-approved symbol, SNCB) is highly expressed in brain including the substantia nigra, the main region of neuronal degeneration in patients with Parkinson disease. "
11/15/2011 - "Alpha- and beta-synuclein expression in Parkinson disease with and without dementia."
|2.||Neurodegenerative Diseases (Neurodegenerative Disease)
01/01/2003 - "Beta-synuclein is a neuronal protein that accumulates in the plaques that characterize neurodegenerative diseases such as Parkinson's and Alzheimer's diseases. "
10/01/2002 - "Such an anti-amyloidogenic property of beta-synuclein might also provide a novel strategy for the treatment of neurodegenerative disorders."
08/01/2002 - "This is considered as preliminary in vivo proof of antiaggregatory function of beta-synuclein and its potential as therapeutic substance for treatment of neurodegenerative disorders linked with abnormal protein aggregation. "
10/25/2001 - "Such an anti-amyloidogenic property of beta-synuclein might also provide a novel strategy for the treatment of neurodegenerative disorders."
11/15/1998 - "We have determined the intron-exon structure of the beta-synuclein gene and established sequencing assays that will facilitate the search for mutations in the beta-synuclein gene in patients with Parkinson disease or other neurodegenerative disorders."
|3.||Lewy Body Disease (Lewy Body Dementia)
12/01/2004 - "An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model."
04/01/2007 - "These results support the contention that in Parkinson's disease and Lewy body dementia, alpha-syn oligomers on the membrane might form pore-like structures, and that the beneficial effects of beta-synuclein might be related to its ability to block the formation of pore-like structures."
10/01/2006 - "Previous studies have shown that beta-synuclein (beta-syn), the homologue of alpha-syn, inhibited alpha-syn aggregation and stabilized Akt cell survival signaling molecule, suggesting that beta-syn was protective against alpha-syn-related neurodegenerative disorders, such as Parkinson's disease and diffuse Lewy body disease. "
01/01/2011 - "Therefore controlling beta-synuclein expression may control the accumulation of alpha-synuclein and ultimately prevent disease progression. "
11/01/2013 - "In this regard, strategies to counter-regulate the expression of the synucleins by increasing beta-synuclein expression relative to alpha-synuclein may be beneficial in preventing disease progression. "
|5.||Alzheimer Disease (Alzheimer's Disease)
08/01/2002 - "Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides."
11/09/1999 - "Pathogenic alpha-synuclein (alphaS) gene mutations occur in rare familial Parkinson's disease (PD) kindreds, and wild-type alphaS is a major component of Lewy bodies (LBs) in sporadic PD, dementia with LBs (DLB), and the LB variant of Alzheimer's disease, but beta-synuclein (betaS) and gamma-synuclein (gammaS) have not yet been implicated in neurological disorders. "
|5.||Proteins (Proteins, Gene)
|6.||Staphylococcal Protein A (A, Protein)
|7.||Caspase 3 (Caspase-3)
|9.||Ciliary Neurotrophic Factor (CNTF)
|10.||Brain-Derived Neurotrophic Factor (BDNF)